{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70","upperLimit":"100","value":"90"},{"groupId":"OG001","lowerLimit":"70","upperLimit":"100","value":"90"}]}],"title":"Baseline (n=337, 304)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-50","upperLimit":"10","value":"0"},{"groupId":"OG001","lowerLimit":"-60","upperLimit":"20","value":"0"}]}],"title":"Change at Week 7 (n=291, 263)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-40","upperLimit":"20","value":"0"},{"groupId":"OG001","lowerLimit":"-60","upperLimit":"20","value":"0"}]}],"title":"Change at Week 15 (n=242, 196)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-90","upperLimit":"20","value":"0"},{"groupId":"OG001","lowerLimit":"-60","upperLimit":"20","value":"0"}]}],"title":"Change at Week 23 (n=195, 143)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-40","upperLimit":"20","value":"0"},{"groupId":"OG001","lowerLimit":"-50","upperLimit":"20","value":"0"}]}],"title":"Change at Week 31 (n=166, 108)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-40","upperLimit":"20","value":"0"},{"groupId":"OG001","lowerLimit":"-20","upperLimit":"10","value":"0"}]}],"title":"Change at Week 43 (n=137, 79)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"304"}],"units":"Participants"}],"description":"Karnofsky performance score is used to quantify participant's general well-being and activities of daily life and participants were classified based on their functional impairment. Karnofsky performance score is 11 level score which ranges between 0 (death) to 100 (no evidence of disease). Higher score means higher ability to perform daily tasks.","dispersionType":"Full Range","groups":[{"description":"Bevacizumab infusions were administered every two weeks at a dose of 10 mg/kg for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.","id":"OG000","title":"Bevacizumab + IFN-Alfa-2A"},{"description":"Placebo matched with Bevacizumab infusions were administered every two weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.","id":"OG001","title":"Placebo + IFN-Alfa-2A"}],"paramType":"MEDIAN","populationDescription":"Safety population: all participants randomized and exposed to study drug (8 randomized participants did not receive study treatment and were not included, 2 in bevacizumab and 6 in placebo group). 12 participants randomized to placebo received bevacizumab, were included in bevacizumab arm. n=number of evaluable participants at specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 7, 15, 23, 31, 43","title":"Change From Baseline in Karnofsky Performance Status","type":"SECONDARY","unitOfMeasure":"score on a scale"}